drugset / Trial / NCT01837329
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The main objective of this study is to determine recommended phase II dose and safety of tetrathiomolybdate (TM) in combination with carboplatin and pemetrexed in chemo-naive metastatic or recurrent non-squamous non-small cell lung cancer.
Timeline
- Start
- 2013-11
- Primary completion
- 2019-01-11
- Completion
- 2019-01-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tetrathiomolybdate | Unknown | 20 mg | Oral |
| Subject | Tetrathiomolybdate | Unknown | 40 mg | Oral |
| Subject | Tetrathiomolybdate | Unknown | 60 mg | Oral |